Eli Lilly News and Activities
Presence
Eli Lilly develops and sells prescription medicines for diabetes, cancer, immunology, and neuroscience. It provides drug research, manufacturing, and related services for patients, healthcare professionals, hospitals, and health systems.
Eli Lilly products and services overview:
- Diabetes medicines
- Cancer treatments
- Immunology therapies
- Neuroscience medicines
- Obesity treatments
- Clinical research services
Revenue: ~$45 billion
Employees: 47,000
Headquarters: Indianapolis, United States (USA)
Eli Lilly is one of the...
- Forbes Global 2000 (#138);
- Fortune 500 (#67);
- Global Fortune 500 (#336);
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Eli Lilly is a company listed under the stock ticker LLY (US).
Eli Lilly has a direct presence in 18 countries.Eli Lilly has 28 subsidiaries including 4E Therapeutics, Adverum Biotechnologies and Akouos.
They are in:
- Pharmaceuticals69%
- Biotechnology21%
- Other10%
Acquisition, funding and merger involving Eli Lilly.
- Eli Lilly has acquired Centessa Pharmaceuticals (posted on June 24 2026).
- Eli Lilly has acquired 4E Therapeutics (posted on June 17 2026).
- Eli Lilly has announced the acquisition of Curevo Vaccine (posted on May 26 2026).
- Eli Lilly has announced the acquisition of LimmaTech Biologics (posted on May 26 2026).
- Eli Lilly has acquired EngageBio (posted on May 22 2026).
- Eli Lilly has acquired Ventyxbio (posted on May 4 2026).
- Eli Lilly has announced the acquisition of Ajax Therapeutics (posted on April 28 2026).
- Eli Lilly has announced the acquisition of Kelonia Therapeutics (posted on April 20 2026).
- Eli Lilly has acquired CrossBridge Bio (posted on April 20 2026).
- Eli Lilly has announced the acquisition of Centessa Pharmaceuticals (posted on March 31 2026).
- Eli Lilly has announced the acquisition of Orna Therapeutics (posted on February 11 2026).
- Eli Lilly has announced the acquisition of Ventyxbio (posted on January 8 2026).
- Eli Lilly has acquired Adverum Biotechnologies (posted on December 10 2025).
- Adverum Biotechnologies and Eli Lilly have announced they will merge (posted on November 26 2025)..
- Eli Lilly has acquired Verve Therapeutics (posted on July 25 2025).
- Eli Lilly has announced the acquisition of Verve Therapeutics (posted on June 17 2025).
- Eli Lilly has announced the acquisition of SiteOne Therapeutics (posted on May 29 2025).
- Eli Lilly has announced the acquisition of Scorpion Therapeutics (posted on January 23 2025).
- Eli Lilly has acquired Morphic Therapeutic (posted on August 20 2024).
- See more news about Eli Lilly Hide news involving Eli Lilly
Executives
View the org chart displaying its 325 main executives
Most searched biographies at Eli Lilly
- David Ricks, President, Chief Executive Officer and Chairman of th...
- Ralph Alvarez, Director
- Jamere Jackson, Director
Popular executive movements at Eli Lilly
- Jean Santana, who was Senior Director, Human Resources Business Partner, Manufacturing and Quality, is promoted to Senior Director, Global People Strategy, Manufacturing and Quality (posted on May 13 2026).
- Jasmine Leong, who was Senior Director of International Market Alzheimer's Diagnostics, is promoted to Executive Director, International Brand, Alzheimer (posted on May 4 2026).
- Fatemeh Akhlaghi has joined the company as Executive Director, Clinical Pharmacology (posted on May 4 2026).
Click here to view some more movements at Eli Lilly
Create your alert
to follow the executive moves at Eli Lilly.
Pharmaceuticals
Eli Lilly has 1,914 competitors including Sanofi (France), Moderna (United States (USA)) and Pfizer (United States (USA)).
Popular M&A news in Pharmaceuticals
- Aurobindo has announced the acquisition of Lannett (posted on June 26 2026).
- Merck has announced the acquisition of Bio-Techne (posted on June 25 2026).
- Eli Lilly has acquired Centessa Pharmaceuticals (posted on June 24 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Eli Lilly
- Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity | Eli Lilly and Company
- Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting | Eli Lilly and Company
- Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks | Eli Lilly and Company
- Lilly Statement on New 340B Litigation | Eli Lilly and Company
- Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium | Eli Lilly and Company
- Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials | Eli Lilly and Company
- Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease | Eli Lilly and Company
- New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis | Eli Lilly and Company
- Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity | Eli Lilly and Company
- Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight | Eli Lilly and Company
- View more press releases Close
Social media about Eli Lilly
- Eli Lilly on Wikipedia, Google News & Yahoo Finance
- Eli Lilly on LinkedIn, X (Twitter) & YouTube
